NICE green light for Merck’s hepatitis C drug Zepatier
Cost regulators for the NHS in England and Wales are backing use of Merck, Sharp & Dohme’s hepatitis C therapy Zepatier, potentially giving patients with certain types of the condition ‘routine’ access to another treatment option.
Read More
